ArticleAmerican journal of translational research2018
MiR-182 promotes cell proliferation by suppressing FBXW7 and FBXW11 in non-small cell lung cancer.
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 51 citations in OpenAlex.
- MicroRNAs as the critical regulators of ubiquitin-proteasome system through F-box protein targeting during tumor progression.Cancer cell international · 2025Review
- Cancer-associated mesenchymal stem cell exosomes facilitate non-small cell lung cancer cell viability and invasiveness by delivering miR-182 in a FBXW7-related AKT and ERK-dependent pathway.Oncology letters · 2025Article
- FBXW11 inhibits tumorigenesis by ubiquitinating YB1 in hepatocarcinoma.Journal of cancer research and clinical oncology · 2025Article
- E3 ubiquitin ligase FBXW11-mediated downregulation of S100A11 promotes sensitivity to PARP inhibitor in ovarian cancer.Journal of pharmaceutical analysis · 2025Article
- Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion.Translational lung cancer research · 2025Article
- Bioinformatics and Experimental Insights Into miR-182, hsa_circ_0070269, and circ-102,166 as Therapeutic Targets for HCV-Associated HCC.Cancer reports (Hoboken, N.J.) · 2024Article
- FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects.Frontiers in pharmacology · 2024Review
- Crosstalk of ubiquitin system and non-coding RNA in fibrosis.International journal of biological sciences · 2024Review
- Unraveling Therapeutic Opportunities and the Diagnostic Potential of microRNAs for Human Lung Cancer.Pharmaceutics · 2023Review
- The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target.Cancer cell international · 2023Review
- Expression of FBXW11 in normal and disease-associated osteogenic cells.Journal of cellular and molecular medicine · 2023Article
- The miR-183 Cluster: Biogenesis, Functions, and Cell Communication via Exosomes in Cancer.Cells · 2023Review
- Different miRNAs Related toInternational journal of molecular sciences · 2023Article
- Association of FBXW11 levels with tumor development and prognosis in chondrosarcoma.Cancer biomarkers : section A of Disease markers · 2022Article
- Pan-cancer analysis of FBXW family with potential implications in prognosis and immune infiltration.Frontiers in immunology · 2022Article
- Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion.Cancer biomarkers : section A of Disease markers · 2022Article
- Article
- FBXW11 contributes to stem-cell-like features and liver metastasis through regulating HIC1-mediated SIRT1 transcription in colorectal cancer.Cell death & disease · 2021Article
- Analysis of miRNA Profiles and the Regulatory Network in Congenital Pulmonary Airway Malformations.Frontiers in pediatrics · 2021Article
- miR-182-5p Serves as an Oncogene in Lung Adenocarcinoma through Binding to STARD13.Computational and mathematical methods in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMicroRNAs have been found to be deregulated in lung cancers, which play crucial roles in tumorigenesis and progression. FBXW7 and FBXW11, two important F-box proteins of the ubiquitin-proteasome system (UPS), can target multiple substrates for degradation, in order to regulate cell proliferation and survival in cancers. In the present study, we aimed to explore the potential role and regulating mechanism of miR-182 in non-small cell lung cancer (NSCLC).
methodsMiRNA expression was evaluated by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). FBXW7, FBXW11, c-Jun, c-Myc and cyclin D protein levels were detected by western blot. Cell growth was determined using cell counting kit (CCK)-8 reagent and colony formation experiment. Then, cell apoptosis and the cell cycle were analyzed on flow cytometry. The target binding activity of miR-182 with FBXW7 or FBXW11 was evaluated through the Dual-Luciferase Reporter Assay System.
resultsIt was confirmed that miR-182 was significantly upregulated in tumor tissues, compared with adjacent normal tissues, and this was inversely correlated to the protein levels of FBXW7 and FBXW11. The overexpression of miR-182 in NSCLC cells dramatically promoted cell growth, colony formation capacity and cell cycle progression, and inhibited apoptosis in NSCLC cells. In contrast, the downregulation of miR-182 significantly alleviated these properties
conclusionThese results bring new insights into the oncogenic role of miR-182 in NSCLC, indicating that miR-182 might be a novel biomarker for the diagnosis and prognosis of NSCLC.
Indexed as
Identifiers
29736206PMC5934572W2979474383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.